

Supplementary Table 5: Summary of patients on immune check point inhibitors and renal transplantation

<i>Publication</i>	<i>Therapy</i>	<i>Time of onset of renal dysfunction in reference to starting</i>	<i>History of any prior cancers</i>	<i>Type of Cancer</i>	<i>Age</i>	<i>Gender</i>	<i>Renal Pathology</i>	<i>Renal transplant information</i>	<i>Renal Outcomes</i>	<i>Cancer Outcome</i>
Lipson et al	Ipilimumab	No AKI with creatinine stable at 1.2mg/dl	None	Metastatic Melanoma	72	Male	NA	DDRT 2000(tacrolimus and prednisone) Tacrolimus was discontinued	Continued to remain stable on the agent even after 2 years	Continued partial response
Lipson et al	Ipilimumab	No AKI with creatinine stable at 2.0mg/dl	None	Metastatic Melanoma	58	Male	NA	DDRT 2004(MMF, tacrolimus and prednisone) MMF and tacrolimus was discontinued	Continued to remain stable	

Supplementary Online Appendix for article for Wanchoo R et al. " Adverse Renal Effects of Immune Check Point Inhibitors: A Narrative Review."

Alhamad et al	Ipilimumab followed by pembrolizumab	5 weeks after last dose of ipilimumab and 3 weeks following last dose of pembrolizumab presented with AKI and a serum creatinine of 8.7 mg/dl (baseline creatinine 1.1mg/dl)	Yes, SCC in 2004 for which patient got carboplatin/paclitaxel and good response	Metastatic Melanoma	68	Male	Mixed cellular active and antibody rejection (BANFF IIA)	DDRT 2000(cyclosporine, prednisone) Cyclosporine discontinued	Steroids tried and low dose tacrolimus but hemodialysis was initiated	Information not provided
Spain et al	Ipilimumab followed by nivolumab	5 weeks after ipilimumab and 1 week after last dose of nivolumab	None	Metastatic Melanoma	48	Male	Acute cellular rejection BANFF IIA	DDRT 2001(prednisone, tacrolimus) Tacrolimus stopped	Started steroids and hemodialysis	Disease progression
Lipson et al	Pembrolizumab For the same cancer was tried on cetuximab, and trametinib with no response	AKI after 8 weeks	None	SCC	57	Female	Acute cellular rejection	DDRT(1989) on prednisone and cyclosporine Cyclosporine was discontinued	Started hemodialysis	85% reduction in tumor

Supplementary Online Appendix for article for Wanchoo R et al. " Adverse Renal Effects of Immune Check Point Inhibitors: A Narrative Review."

Bolis et al.	Nivolumab	AKI after 6 weeks	None	Non Small cell lung cancer of lung	75	Male	Acute cellular rejection (BANFF IIB)	Not mentioned which form of transplant but on cyclosporine and prednisone	Prednisone and dialysis	Information not provided
Barnett et al	Nivolumab	No AKI	None	Duodenal cancer	70	Male	No	LRRT(2010)	Preventive prednisone and sirolimus given (tacrolimus and MMF stopped)	85% reduction of tumor

AKI: Acute kidney injury, DDRT: Deceased Donor renal transplant, SCC: squamous cell carcinoma; LRRT: living related renal transplant